Floatz logo

ARA-GUANOSINE

Clear Cell Renal Cell Carcinoma

M.D. Anderson Cancer CenterSmall moleculePhase 1/2Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
73/ 100

Competitive context

62 Active assets in the Clear Cell Renal Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Girentuximab
Massachusetts General Hospital
Phase 3BB
gw786034
Academic and Community Cancer Research United
Phase 4BB
su011248
Pfizer
Phase 4BB
Nivolumab
Fred Hutchinson Cancer Center
Phase 3BB
Bms-907351
SWOG Cancer Research Network
Phase 3BB

View all 50 →

Same molecule, other indications

ARA-GUANOSINE is also rated in:

Alzheimer Disease (AD)Dormant
CCC
Indicative ·
52 / 100
View asset →
Correlate Tracer Uptake to TCell Tumor Infiltration & CkIT BenefitDormant
CCC
Indicative ·
52 / 100
View asset →
Non-small Cell Lung CancerDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →